These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Completed, but no date||2005-000690-22||A phase II Clinical Study of CP-4055 in patients with metastatic melanoma not previous treated with chemotherapy||bad-data|
|Exempt||2006-000868-83||A Phase I/II Study of CP-4055 in Patients with Refractory/Relapsed Hematologic Malignancies||2009-07-02||not-yet-due|
|Ongoing||2006-006766-41||A phase II Clinical Study of CP-4055 as second line therapy in patients with advanced colorectal cancer||not-yet-due|
|Not reported||2007-000915-28||A multicentre, dose finding, phase II Study of CP-4055 in combination with Sorafenib in patients with metastatic malignant melanoma||2008-08-25||due-trials|
|Completed, but no date||2007-003323-20||A Phase I/II Study of CP-4055 in Patients with Platinum Resistant Ovarian Cancer||bad-data|
|Ongoing||2007-007476-42||A phase II study of CP-4126 in patients with advanced pancreatic cancer||not-yet-due|
|Listed as ongoing, but also has a completion date||2008-008518-38||A Phase II Study of CP-4055 plus Idarubicin as Second Course Remission-Induction Therapy in Patients with Acute Myeloid Leukaemia||2013-05-07||bad-data|
|Listed as ongoing, but also has a completion date||2009-014445-80||A Randomised Phase III Study of Elacytarabine vs. Investigator’s Choice in Patients with Late Stage Acute Myeloid Leukaemia||2013-05-17||bad-data|